Pharmacovigilance II. Side Effects and the International Drug Monitoring Program

J Leticia Rodríguez Betancourt; José Luis García Vigil; Carmen Giral Barnés; David Hernández Santillán; Luis Jasso Gutiérrez

2004, Number 5

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2004; 42 (5)

Pharmacovigilance II. Side Effects and the International Drug Monitoring Program

Rodríguez BJL, García VJL, Giral BC, Hernández SD, Jasso GL

Full text

How to cite this article

Language: Spanish
References: 16
Page: 419-423
PDF size: 143.07 Kb.

ABSTRACT

This article includes the international definition of adverse drug reactions and some other definitions adopted in other countries and their classification. Also briefly describes the final goal pursued, at the Collaborating Center with the suspected adverse drug reactions reports of the countries participating in The International Drug Monitoring Program. Finally, it reviews shortly the international, national, and institutional benefits of the Pharmacovigilance Program.

REFERENCES

Rodríguez-Betancourt JL, García-Vigil JL, Giral-Barnés C, Hernández-Santillán D, Jasso-Gutiérrez L.Farmacovigilancia I. El inicio. Rev Med IMSS 2004;42(4):327-329.
Organización Mundial de la Salud. Vigilanciafarmacológica internacional. Función del hospital.Informe de una reunión de la OMS. Ginebra,Suiza: Organización Mundial de la Salud, Serie deInformes Técnicos, número 425; 1969.
Edwards IR, Biriell C. Harmonization in pharmaco-vigilance. Drug Safety 1994;10 (2): 93-102.
World Health Organization. The Uppsala MonitoringCentre. Safety monitoring of medicinal products.Guidelines for setting up and running a pharmaco-vigilance centre. Uppsala, Sweden: WHO CollaborationCentre for International Drug Monitoring; 2000.
The Uppsala Monitoring Centre. http//www.who-umc.org. Consultada en mayo del 2004.
Meyboom RHB, Lindquist M, Flygare AK, BiriellC, Edwards IR. The value of reporting therapeuticineffectiveness as an adverse drug reaction. DrugSafety 2000;23(2):95-99.
Medicines and Healthcare products RegulatoryAgency. http://www.mca.gov.uk. Consultada enmayo del 2004.
Rawlins MD, Thompson JW. Pathogenesis ofadverse drug reactions. En: Davies DM, editor.Davies™s textbook of adverse drug reactions. NewYork, USA: Oxford University Press; 1977. p. 44.
Meyboom RHB, Lindquist M, Egberts AAC. AnABC of drug related problems. Drug Safety 2000;22(6):416-423.
Rawlins MD, Thomas SLH. Mechanisms of adversedrug reactions. En: Davies DM, Ferner RE, DeGlanville H, editors. Davies™s textbook of adversedrug reactions. London, England: Chapman andHall Medical; 1998. p. 40-59.
Strom BL. Sample size considerations for pharmaco-epidemiology studies. En: Strom BL, editor. Pharma-coepidemiology. New York, USA: John Wiley andSons; 1994. p. 29-38.
Lindquist AM. Seeing and observing in internationalpharmacovigilance. Uppsala, Sweden: The UppsalaMonitoring Centre; 2003.
Edwards IR, Lindquist M, Wiholm B-E, Napke E.Quality criteria for early signals of possible adversedrug reactions. Lancet 1990;336:156-158.
Lindquist M, Edwards IR, Bate A, Fucik H, NuñezAM, Stahl M. From association to alert. A revisedapproach to international signal analysis. Pharmaco-epidemiology and Drug Safety 1999;8:S15-S25.
Meyboom RHB, Egberts ACG, Edwards IR,Hekster YA, de Koning HP, Gribnau FWJ. Prin-ciples of signal detection in pharmacovigilance.Drug Safety 1997;16(6):355-365.
Bate A, Lindquist M, Edwards IR, Olsson S, OrreR, Lansner A, et al. A bayesian neural networkmethod for adverse drug reaction signal generation.Eur J Clin Pharmacol 1998;54:315-321.